North, Khrystyna http://orcid.org/0000-0003-3885-870X
Benbarche, Salima http://orcid.org/0000-0001-5314-0435
Liu, Bo
Pangallo, Joseph
Chen, Sisi
Stahl, Maximilian
Bewersdorf, Jan Philipp
Stanley, Robert F. http://orcid.org/0000-0002-2308-6914
Erickson, Caroline
Cho, Hana
Pineda, Jose Mario Bello
Thomas, James D.
Polaski, Jacob T.
Belleville, Andrea E.
Gabel, Austin M.
Udy, Dylan B.
Humbert, Olivier
Kiem, Hans-Peter http://orcid.org/0000-0001-5949-4947
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
Bradley, Robert K. http://orcid.org/0000-0002-8046-1063
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA251138, R01 CA251138)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL128239, R01 HL128239)
Article History
Received: 15 December 2020
Accepted: 17 January 2022
First Online: 3 March 2022
Competing interests
: O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine Inc., Merck, Prelude Therapeutics and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., Pfizer Boulder and AIChemy Inc. O.A.-W. has received previous research funding from Loxo Oncology and H3B Biomedicine unrelated to the current paper. K.N., S.B., B.L., O.A.-W. and R.K.B. are inventors on a patent application submitted by Fred Hutchinson Cancer Research Center related to this work. The remaining authors declare no competing interests.